{"id":40314,"date":"2001-04-01T12:08:00","date_gmt":"2001-04-01T10:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/leserbrief-glibenclamid-bei-gestationsdiabetes"},"modified":"2001-04-01T12:08:00","modified_gmt":"2001-04-01T10:08:00","slug":"leserbrief-glibenclamid-bei-gestationsdiabetes","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/","title":{"rendered":"Leserbrief: Glibenclamid bei Gestationsdiabetes?"},"content":{"rendered":"<p>Dres. H.K. aus Kiel und U.S.-G. aus Berlin schreiben: >> In der Novemberausgabe 2000 des ARZNEIMITTELBRIEFS (1) wird \u00fcber eine randomisierte Studie von O. Langer et al. (2) berichtet, die Wirksamkeit und Sicherheit von Glibenclamid im Vergleich zu Humaninsulin bei \u00fcber 400 Frauen im Alter von 18 bis 44 Jahren untersucht. Die Autoren dieser Studie [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dres. H.K. aus Kiel und U.S.-G. aus Berlin schreiben: >> In der Novemberausgabe 2000 des ARZNEIMITTELBRIEFS (1) wird \u00fcber eine randomisierte Studie von O. Langer et al. (2) berichtet, die Wirksamkeit und Sicherheit von Glibenclamid im Vergleich zu Humaninsulin bei \u00fcber 400 Frauen im Alter von 18 bis 44 Jahren untersucht. Die Autoren dieser Studie [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[216,5096,6586],"class_list":["post-40314","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-diabetes-mellitus","tag-gestationsdiabetes","tag-schwangerschaftsdiabetes"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Dres. H.K. aus Kiel und U.S.-G. aus Berlin schreiben: &gt;&gt; In der Novemberausgabe 2000 des ARZNEIMITTELBRIEFS (1) wird \u00fcber eine randomisierte Studie von O. Langer et al. (2) berichtet, die Wirksamkeit und Sicherheit von Glibenclamid im Vergleich zu Humaninsulin bei \u00fcber 400 Frauen im Alter von 18 bis 44 Jahren untersucht. Die Autoren dieser Studie [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2001-04-01T10:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Leserbrief: Glibenclamid bei Gestationsdiabetes?\",\"datePublished\":\"2001-04-01T10:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/\"},\"wordCount\":520,\"keywords\":[\"Diabetes mellitus\",\"Gestationsdiabetes\",\"Schwangerschaftsdiabetes\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/\",\"name\":\"Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2001-04-01T10:08:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/leserbrief-glibenclamid-bei-gestationsdiabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leserbrief: Glibenclamid bei Gestationsdiabetes?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/","og_locale":"de_DE","og_type":"article","og_title":"Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief","og_description":"Dres. H.K. aus Kiel und U.S.-G. aus Berlin schreiben: >> In der Novemberausgabe 2000 des ARZNEIMITTELBRIEFS (1) wird \u00fcber eine randomisierte Studie von O. Langer et al. (2) berichtet, die Wirksamkeit und Sicherheit von Glibenclamid im Vergleich zu Humaninsulin bei \u00fcber 400 Frauen im Alter von 18 bis 44 Jahren untersucht. Die Autoren dieser Studie [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2001-04-01T10:08:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Leserbrief: Glibenclamid bei Gestationsdiabetes?","datePublished":"2001-04-01T10:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/"},"wordCount":520,"keywords":["Diabetes mellitus","Gestationsdiabetes","Schwangerschaftsdiabetes"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/","name":"Leserbrief: Glibenclamid bei Gestationsdiabetes? - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2001-04-01T10:08:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/leserbrief-glibenclamid-bei-gestationsdiabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Leserbrief: Glibenclamid bei Gestationsdiabetes?"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40314"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}